Skip to content

Shionogi, Energetic Citizenship Community and MEPS Advocate for Pressing Coverage Implementation in EU Member States at EU Parliament Occasion to Deal with the Rising Menace of Antimicrobial Resistance


  • Final week, Shionogi partnered with the Energetic Citizenship Community and members of the European Parliament (MEPs) to host an EU Parliament occasion calling for collaboration to drive coverage change and implementation within the struggle towards antimicrobial resistance (AMR) inside the EU and member states.

  • Pressing motion is required to encourage and help the invention and growth of novel antibiotics in addition to entry fashions that reward innovation and applicable use to handle the rising menace of AMR

  • Though AMR is a slower shifting menace, it’s no much less harmful than COVID-19: in 2019, there have been an estimated 1.27 million deaths attributable to bacterial AMR1 and future projections for the affect of unresolved AMR are as excessive as 10 million deaths per 12 months by 2050two

OSAKA, Japan & AMSTERDAM, November 21, 2022–(BUSINESS WIRE)–Shionogi & Co., Ltd. and its European subsidiary, Shionogi BV (hereafter “Shionogi”), held an occasion on the EU Parliament final week within the run-up to World Antimicrobial Consciousness Week, becoming a member of forces with MEPs, Energetic Citizenship Community and MEPs Curiosity Group on “European Sufferers’ Rights & Cross-Border Healthcare” to debate initiatives to sort out AMR. The occasion strengthened the necessity for pressing consideration and collaboration from pharmaceutical firms, coverage stakeholders and governments to result in coverage change and innovation to handle this rising problem.

The European Well being Union has declared AMR one in all its high three precedence well being threats within the EU requiring pressing consideration and motion. Inside the context of the revision of the Pharmaceutical Laws and the deliberate European Council Suggestions on AMR going down in This fall 2022, the occasion introduced collectively high-level European policymakers to debate the innovation framework for the event of recent antibiotics primarily based on concrete examples of initiatives carried out by nationwide well being authorities to struggle AMR. The occasion additionally explored collaborative and governance fashions to realize higher implementation of actions and greatest practices for a holistic AMR method.

“The assembly was essential to extend consciousness of Antimicrobial Resistance and the necessity for brand new improvements to handle unmet wants. I am calling on affected person organisations, business, the European Fee, academia, and healthcare professionals to work collectively to drive coverage change and put in place a typical response to this rising societal problem,” stated MEP Aldo Patriciello.

“The inclusion of the AMR inside the work program of the incoming Sweden Presidency of the Council of the EU and the prioritization of the subject by the European Well being Emergency Preparedness and Response Authority (HERA) make it possible to advance coverage motion to enhance stewardship, surveillance of resistance patterns throughout Europe and incentivise innovation.These actions must be absolutely built-in into One Well being Methods offering options for human, animal and environmental well being.The involvement of civic society and affected person advocacy teams can also be essential within the growth and implementation of AMR Nationwide Plans” commented Mariano Votta, Director of Energetic Citizenship Community, the EU department of the Italian NGO Cittadinanzattiva.

MEP Fabio Massimo Castaldo additionally affirmed the significance of growing a predictable regulatory surroundings to incentivise non-public investments in new antibiotics, along with organising fast procurement and buy mechanisms for crisis-relevant medical countermeasures to answer rising threats and higher put together European well being methods. He said that “With the adoption of the International Well being Technique and Pharmaceutical Laws Assessment, the time to behave is now, and as Members of the European Parliament, we are going to totally evaluate these proposals to make sure it meets the target and ambition which can be wanted.”

In 2019, bacterial AMR was instantly accountable for 1.27 million deaths and related to practically 5 million deaths.two Future projections for the affect of unresolved AMR are as excessive as 10 million deaths per 12 months by 2050.3 Antibiotics are essential for each facet of modern-day healthcare, from widespread surgical procedures to chemotherapy and organ transplants. Except pressing motion is taken, we might face a future during which a scarcity of efficient antibiotics might make routine medical procedures harmful, make extra advanced interventions and procedures unattainable, and cut back our capacity to answer outbreaks of infectious ailments. Tedros Adhanom Ghebreyesus, Director Common on the World Well being Group (WHO) has known as it a ‘sluggish tsunami that threatens to undo a century of medical progress’.

We all know that incentivising innovation is essential as a way to stimulate antimicrobial R&D and a pipeline of recent and efficient antibiotics, and that is needed at each a European and native nation degree. We’ve seen particular examples of profitable fashions which have been applied in European nations and urge different EU member states to comply with go well with and take into account comparable incentives to assist tackle the challenges confronted in bringing novel antibiotics to market,” commented Mark Hill, Senior Vice President, International Head of Worth and Entry, Shionogi.

Whereas growing antibiotics is an extended, expensive and unsure course of, commercialization may also be difficult. As soon as launched, understandably, there may be typically a low frequency of use pushed by the necessity for stewardship to forestall resistance growth. Low use results in restricted revenues, which in flip restricts continued commercialization and new product analysis. Because of these financial challenges, many giant pharmaceutical firms are not lively within the growth and commercialization of antibiotics, and several other smaller biotech firms have filed for chapter. Shionogi strongly helps the introduction of recent incentives, funding and worth evaluation fashions for reimbursement to revive a viable industrial market to handle the financial problem confronted in bringing novel antibiotics to market, whereas selling stewardship.

Shionogi is dedicated to sustaining the momentum and leveraging collaborations with civil society, policymakers, business, academia, and healthcare professionals to champion innovation to collectively flip the tide within the struggle towards AMR.

Antimicrobial resistance (AMR)

Antimicrobial resistance (AMR) is a serious well being burden which urgently must be addressed. Infections brought on by carbapenem-resistant Gram-negative micro organism are sometimes related to a excessive mortality price.3 If no motion is taken, antibiotic resistance is predicted to kill 10 million individuals yearly by 2050, at a cumulative price to international financial output of 100 trillion USD.3

Shionogi’s dedication to preventing antimicrobial resistance

Shionogi has a powerful heritage within the subject of anti-infectives and has been growing antimicrobial therapies for greater than 60 years. Shionogi is proud to be one of many few giant pharmaceutical firms that continues to give attention to analysis and growth in anti-infectives. The corporate invests the very best proportion of its pharmaceutical revenues in related anti-infectives R&D in comparison with different giant pharmaceutical firms.4

For extra info please check with:

About Shionogi
Shionogi & Co., Ltd. is a 142-year-old international, analysis pushed pharmaceutical firm headquartered in Osaka, Japan, that’s devoted to bringing advantages to sufferers primarily based on its company philosophy of “supplying the very best medication to guard the well being and wellbeing of the sufferers we serve.” The corporate at present markets merchandise in a number of therapeutic areas together with anti-infectives, ache, CNS problems, cardiovascular ailments and gastroenterology. Shionogi’s analysis and growth at present goal two therapeutic areas: infectious ailments, and ache/CNS problems.

For extra info on Shionogi & Co., Ltd., please go to

Shionogi BV is the European headquarters of Shionogi & Co., Ltd. For extra info on Shionogi BV, please go to

Ahead-Wanting Statements
This announcement comprises forward-looking statements. These statements are primarily based on expectations in gentle of the data at present out there, assumptions which can be topic to dangers and uncertainties which might trigger precise outcomes to vary materially from these statements. Dangers and uncertainties embody common home and worldwide financial situations reminiscent of common business and market situations, and adjustments of rate of interest and foreign money alternate price. These dangers and uncertainties notably apply with respect to product-related forward-looking statements. Product dangers and uncertainties embody, however are usually not restricted to, completion and discontinuation of medical trials; acquiring regulatory approvals; claims and considerations about product security and efficacy; technological advances; adversarial final result of great litigation; home and overseas healthcare reforms and adjustments of legal guidelines and laws. Additionally for current merchandise, there are manufacturing and advertising and marketing dangers, which embody, however are usually not restricted to, lack of ability to construct manufacturing capability to fulfill demand, lack of availability of uncooked supplies and entry of aggressive merchandise. The corporate disclaims any intention or obligation to replace or revise any forward-looking statements whether or not because of new info, future occasions or in any other case.

© 2022 Shionogi Europe. All Rights Reserved.


1 Antimicrobial Resistance Collaborators. International burden of bacterial antimicrobial resistance in 2019: a scientific evaluation. Lancet. 2022;399:629-655. doi: Accessible on-line: Final accessed November 2022.

two O’Neill, J.. et al. Assessment on antimicrobial resistance. Tackling drug-resistant infections globally: ultimate report and proposals. 2016 Final accessed November 2022

3 Perez F, et al. ‘Carbapenem-Resistant Enterobacteriaceae: A Menace to our Most Weak Sufferers’. Cleve Clin J Med. Apr 2013; 80(4):225–33

4 Antimicrobial Resistance Benchmark 2021. Final accessed November 2022

Job code: NP-EU-FDC-0398
Date of preparation: November 2022

View supply model on


For additional info, contact:
Shionogi BV
jo taylor
Government Director, Company and Authorities Affairs
Havas SO Media Contact
nicola lilley
Affiliate Director
+44 (0)20 3196 9912

Leave a Reply

Your email address will not be published. Required fields are marked *